• Askin Esen Hasturk, Erdal Resit Yilmaz, Erhan Turkoglu, Hayri Kertmen, Bahriye Horasanli, Nazli Hayirli, Imge Berrin Erguder, and Oya Evirgen.
• Department of Neurosurgery, Oncology Training and Research Hospital, Ankara, Turkey. aehasturk@yahoo.com.
• Ulus Travma Acil Cer. 2015 Jan 1;21(1):1-8.

BackgroundThe aim of this study was to evaluate the therapeutic efficiency of Anakinra, an IL-1ß antagonist with anti-inflammatory effects, in an experimental model of traumatic brain injury (TBI).MethodsFifty-four rats underwent TBI after a weighted object was dropped onto a metal disc secured to their skulls. Animals were randomized into 3 main groups: control (n=18), TBI + saline (n=18; six animals per time-point) with samples obtained at the first, sixth and twenty-fourth h postoperatively, and TBI + Anakinra (n=18; six animals per time-point) with brain samples obtained at the first, sixth and twenty-fourth h postoperatively. Brain tissue and blood serum were extracted for the analysis of IL-1ß, malondialdehyde, glutathione peroxidase, superoxide dismutase, and catalase levels. Tissue sections were evaluated histopathologically under a light microscope.ResultsAfter trauma, tissue and serum IL-1ß levels were significantly elevated and after Anakinra administration, these levels substantially decreased. Glutathione peroxidase, superoxide dismutase, and catalase activity decreased following TBI and Anakinra administration proved effective in increasing the activity of these antioxidant enzymes. Histopathological analysis confirmed that Anakinra might protect the brain tissue and nerve cells from injury.ConclusionResults demonstrate that Anakinra reduces the development of inflammation and tissue injury events associated with TBI.

33 keywords...

hide…